VSANasdaqServices-Educational ServicesUS GAAP · USD

VisionSys AI Inc

VisionSys AI Inc is a U.S.-listed Cayman Islands holding company focused on brain-machine interaction technologies and AI-enabled software and hardware systems. Its business centers on developing solutions that combine core algorithms, connected devices, and applied AI for healthcare and biotechnology use cases.

Revenue1.0m USD
−99.9 %y/y
Operating profit (EBIT)-40.0m USD
+92.1 %y/y
EBIT margin-3,848.0%
−3,804.8 ppy/y
Net income1,719m USD
+392.8 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-1,00001,0002,0003,000m USD2020: 1,898 m USD2020: EBIT -806 m USD20202021: 2,387 m USD2021: EBIT -369 m USD20212022: 2,468 m USD2022: EBIT 93 m USD20222023: 1,375 m USD2023: EBIT 13 m USD20232024: 1,171 m USD2024: EBIT -506 m USD20242025: 1.0 m USD2025: EBIT -40 m USD20251.0-40
RevenueOperating profit (EBIT)

Business

Share of revenue
Brain-machine interaction systems40 %

Core technologies and systems that connect neural or human input with machine interfaces.

AI software platforms25 %

Software and algorithmic tools used to power intelligent decision-making and interaction.

Hardware systems20 %

Related devices and hardware components used alongside the company's software stack.

Healthcare AI solutions15 %

Applied AI products designed for healthcare workflows and clinical-adjacent use cases.

Customers

The company appears to serve healthcare, biotechnology, and adjacent technology customers that need specialized AI and human-machine interaction tools. Its products are likely purchased by organizations seeking applied systems rather than generic software, which makes technical performance and domain fit especially important.

Healthcare organizations

Buy AI-enabled systems for healthcare applications and operational use cases.

Biotechnology companies

Use intelligent systems and software tools for biotech-related workflows.

Technology and research users

Adopt brain-machine interaction and software-hardware solutions for specialized applications.

Strategy

The company's strategy is centered on building AI-driven brain-machine interaction offerings and applying them to healthcare and biotechnology markets. Its positioning suggests an emphasis on technical differentiation, combining algorithms, software, and hardware to create integrated solutions with domain-specific utility.

Advance brain-machine interaction technologyMedium term

This is the core technology platform and the main source of differentiation.

Expand healthcare and biotech use casesMedium term

These end markets provide the clearest commercialization path for applied AI tools.

Maintain access to capital marketsShort term

A U.S. listing supports financing, visibility, and investor access for a specialized technology business.

Geography

VisionSys AI Inc is organized as a Cayman Islands company with a principal executive office in Hebei Province, China, while being listed in the United States through ADSs. The available filings indicate a cross-border operating footprint rather than a single-country business, but they do not disclose a revenue geography split.

Risks

VisionSys AI Inc faces development, commercialization, and regulatory risks typical of early-stage AI and healthtech businesses. Because its products sit at the intersection of software, hardware, and healthcare applications, execution risk and the need for continued technical validation are likely material.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Technology execution risk1Commercial adoption risk2Regulatory and compliance risk3Cross-border governance risk4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Technology execution riskImpact: HighLikelihood: Medium

    Brain-machine interaction and AI systems require reliable performance and sustained development.

    Exposure: Core product platform

  2. Commercial adoption riskImpact: HighLikelihood: Medium

    Specialized AI products may be difficult to sell without clear proof of value and customer validation.

    Exposure: Healthcare and biotech customers

  3. Regulatory and compliance riskImpact: MediumLikelihood: Medium

    Healthcare-adjacent products can face approval, data, and compliance scrutiny.

    Exposure: AI healthcare solutions

  4. Cross-border governance riskImpact: MediumLikelihood: Medium

    The company is incorporated in the Cayman Islands with operations in China and a U.S. listing.

    Exposure: Corporate structure and reporting

Accounting

Judgemental items
Revenue recognition

Future contracts may combine software, hardware, and services with different timing of delivery.

Impact: Can affect timing of reported revenue and margins

Development costs

AI and hardware businesses often face judgment on whether costs are expensed or capitalized.

Impact: Affects operating loss, assets, and amortization

Foreign currency translation

Operations and executive offices are outside the U.S. while the company reports to U.S. investors.

Impact: Can affect reported equity and earnings volatility

Publicly listed companies with a comparable business focus.

Last updated: 28/09/2026

VisionSys AI Inc (Nasdaq) – Services-Educational Services | Financial Analysis – Clarifo